Labopharm is notified of Actavis' filing for a generic Oleptro

11/14/2010 | Reuters

Actavis has notified Labopharm of its FDA filing for a generic version of Oleptro, the latter's once-daily treatment for depression. Labopharm, which is reviewing the formal notice, has market exclusivity for the drug through Feb. 2, 2013.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC